Bristol-Myers to buy Amylin for about $5.3 billion






Bristol-Myers to buy Amylin for about $5.3 billion



(Reuters) - Bristol-Myers Squibb Co has agreed to buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion, or $31 per share, in cash, giving Bristol-Myers a stake in the future of diabetes drugs Byetta and Bydureon. Bristol-Myers said late on Friday it had also reached a follow-on deal with UK-based AstraZeneca Plc to collaborate on the development of Amylin's products once the buyout is completed. AstraZeneca will pay $3.4 billion in cash for these rights. The boards of directors at Amylin, Bristol and AstraZeneca have approved the two transactions, the companies said. ...






Popular posts from this blog

A preview of what we might see at Google I/O 2012

Greece opens detention camp for immigrants as election looms

Tropical Storm Isaac heads for U.S. Gulf Coast